

Freedom of Information Act 2000 - Request Reference Fol/21/449
Anti-VEFG Treatments for Eye Conditions

Request Details

I would greatly appreciate if you could answer the following questions:

1. For the 4-month period from May to August 2021, how many patients has your trust treated with the following anti-VEGF treatments:

- Aflibercept
961
- Bevacizumab
23 (best estimate as most issues were as ward-stock)
- Brolucizumab
0
- Dexamethasone
20
- Fluocinolone acetonide
0
- Ranibizumab
1336

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

- Aflibercept
1146
- Bevacizumab
0
- Brolucizumab
0
- Dexamethasone
0
- Fluocinolone acetonide
0
- Ranibizumab
1557

3. Within your trust, how many intra-vitreous injections/implants of each following treatments have been used (for any eye condition) in the four-month period from May to August 2021:

- Aflibercept
- Bevacizumab

- Brolucizumab
- Dexamethasone
- Ranibizumab

Please refer to question 1.

4. If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from May to August 2021 for Wet Age Related Macular Degeneration (wAMD) ONLY

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Ranibizumab

Please refer to question 1.